317 related articles for article (PubMed ID: 34927457)
21. Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.
Görtz GE; Moshkelgosha S; Jesenek C; Edelmann B; Horstmann M; Banga JP; Eckstein A; Berchner-Pfannschmidt U
Endocrinology; 2016 Oct; 157(10):3771-3778. PubMed ID: 27552248
[TBL] [Abstract][Full Text] [Related]
22. An Early Wave of Macrophage Infiltration Intertwined with Antigen-Specific Proinflammatory T Cells and Browning of Adipose Tissue Characterizes the Onset of Orbital Inflammation in a Mouse Model of Graves' Orbitopathy.
Philipp S; Horstmann M; Hose M; Daser A; Görtz GE; Jesenek C; Flögel U; Hansen W; Bechrakis N; Banga JPS; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2022 Mar; 32(3):283-293. PubMed ID: 34779257
[No Abstract] [Full Text] [Related]
23. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.
Turcu AF; Kumar S; Neumann S; Coenen M; Iyer S; Chiriboga P; Gershengorn MC; Bahn RS
J Clin Endocrinol Metab; 2013 May; 98(5):2153-9. PubMed ID: 23482611
[TBL] [Abstract][Full Text] [Related]
24. Modulating TSH Receptor Signaling for Therapeutic Benefit.
Krause G; Eckstein A; Schülein R
Eur Thyroid J; 2020 Dec; 9(Suppl 1):66-77. PubMed ID: 33511087
[TBL] [Abstract][Full Text] [Related]
25. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
26. Signal responses to neutral TSH receptor antibody - A cycle of damage in the pathophysiology of Graves' disease.
Morshed S; Latif R; Davies TF
J Autoimmun; 2023 Apr; 136():103012. PubMed ID: 36898184
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
28. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
29. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
30. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
31. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
32. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
33. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
34. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
[TBL] [Abstract][Full Text] [Related]
35. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
[TBL] [Abstract][Full Text] [Related]
36. Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene.
Wu R; Li N; Wang X; Wang S; Tan J; Wang R; Zheng W
J Endocrinol Invest; 2024 Apr; ():. PubMed ID: 38662129
[TBL] [Abstract][Full Text] [Related]
37. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
38. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation.
Smith TJ
Autoimmunity; 2003; 36(6-7):409-15. PubMed ID: 14669949
[TBL] [Abstract][Full Text] [Related]
39. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
